General Information of Drug (ID: DMDPM67)

Drug Name
AZD9592 Drug Info
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMDPM67

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Proto-oncogene c-Met (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [3]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [4]
Amivantamab DMZ7AMY Non-small-cell lung cancer 2C25 Approved [5]
Capmatinib DMYCXKL Non-small-cell lung cancer 2C25.Y Approved [6]
Tepotinib DMUQ0E8 Non-small-cell lung cancer 2C25 Approved [7]
RG3638 DMTQJE0 Gastric adenocarcinoma 2B72 Phase 3 [8]
Savolitinib DMALFKX Renal cell carcinoma 2C90 Phase 3 [9]
Beperminogene perplasmid DM6RWBN Critical limb ischemia BD4Y Phase 3 [10]
Tivantinib DMNVP8Q Hepatocellular carcinoma 2C12.02 Phase 3 [11]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [8]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [12]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [13]
Gefitinib DM15F0X Colon adenocarcinoma Approved [14]
Erlotinib DMCMBHA Adrenal gland neoplasm Approved [15]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [16]
Dacomitinib DMOH8VY Non-small-cell lung cancer 2C25.Y Approved [17]
BIBW 2992 DMTKD7Q Non-small-cell lung cancer 2C25.Y Approved [18]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [19]
Epidermal growth factor DMVONE6 Vulnerary ND56.Z Approved [17]
Merimepodib DM0HS92 Breast cancer 2C60-2C65 Approved [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Not Available [2]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05647122) A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of Exelixis (2011).
5 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
12 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
13 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
14 Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
15 Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
16 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
18 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
19 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
20 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).